14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.003 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Variability of PspC (Pneumococcal surface protein C) in strains isolated in the University Hospital of the University of São Paulo (Brazil) A. T. Moreno 1 , D. M. Ferreira 1 , F. C. Pimenta 2 , S. R. Santos 3 , M. B. Martinez 3 , E. Miyaji 1 1 Instituto Butantan, Sao Paulo, Brazil, 2 Centers for Disease Control and Prevention, Atlanta, GA, USA, 3 Hospital Universitario, Sao Paulo, Brazil Background: Streptococcus pneumoniae is one of the most common causes of respiratory tract infections. The vaccine composed of different capsular polysaccharides (PS) purified from pneumococci has low efficacy in children and the elderly, besides not being able to induce immunological memory. Although the 7-valent PS vaccine conjugated to CRM197 was an advance, the production cost is still a major barrier for its widespread use. A proposal to increase vaccine coverage at a low cost consists in the identification of protein antigens present in all pneumococcal isolates. PspC (Pneumococcal surface protein C) has been described for its role in both colonization of the nasopharynx and in invasive infection. PspC is highly polymorphic, being divided into 11 groups. Thus, the evaluation of the variability of this antigen in clinical samples is of great importance to determine the ideal vaccine formulation. Methods: Pneumococcal strains were obtained from the University Hospital of the University of São Paulo (Brazil). Strains were serotyped by PCR and 13 isolates were chosen based on the serotypes present in the new 13-valent conjugate vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). The complete pspC locus was cloned and the gene was sequenced for each isolate. BALB/c mice were immunized with two different recombinant PspC variants for the production of antibodies that were used for Western blot analysis. Results: From the 13 pneumococcal isolates analyzed, six were found to be from group 3, three isolates from group 6, one isolate from group 5, one isolate from group 8 and one isolate from group 9. A duplication containing PspC from group 4 and from group 10 was also found. An antiserum raised against PspC3 was able to recognize the majority of pneumococcal extracts in Western Blot analysis, showing a broad cross-reactivity. On the other hand, an antiserum raised against PspC8 was able to recognize only the isolate expressing PspC from group 8. Conclusion: These preliminary results suggest that PspC3 would be a suitable vaccine antigen, being able to induce antibodies with broad cross-reactivity. Financial support: FAPESP, Fundação Butantan and CNPq.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.004 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Combination of whole cell pertussis vaccine and the pneumococcal surface protein A (PspA) antigen: proposal of a combined vaccine against pertussis and pneumococcal diseases M. L. Sarno de Oliveira, D. M. Ferreira, A. T. Moreno, P. C. D. Ferreira, E. Miyaji, P. Ho Instituto Butantan, Sao Paulo, Brazil Background: Streptococcus pneumoniae (pneumococcus) is one of the major agents of respiratory acute diseases, accounting for 1 million deaths per year around the world. In developing countries, pneumococcal diseases kill 800,000 children annually. PspA is a surface pneumococcal antigen, shown to elicit protection against animal models of pneumococcal infections, in different vaccine formulations. The whole cell pertussis vaccine (WCP) is widely used in developing countries and its first dose is indicated to be given at 2 months of age. As an inactivated bacteria-based vaccine, it has the potential to exert adjuvant activity upon coadministration with other antigens. Methods: Here, we analyzed the adjuvant activity of WCP in combination with PspA and tested the efficacy of WCP-PspA nasal vaccination against a pneumococcal challenge in mice. Results: Nasal immunization of Balb/C mice with WCP-PspA elicited higher amounts of anti- PspA IgG and sIgA than the immunization with PspA alone. Mice immunized with the combination were 100% protected after a respiratory lethal challenge, whereas immunization with PspA alone produced around 60% protection. In time course experiments of challenged mice, IL-6, TNF and IFN-g cytokine signaling was observed in vaccinated animals, with a peak 12h after challenge followed by a quick reduction in secretion, indicating controlled inflammatory responses. In contrast, cytokine secretion in control mice remained high long after challenge, showing that these animals are unable to control the inflammatory response elicited by pneumococcal infection. Pneumococci loads increase in the lungs of control animals and reach the bloodstream 30h after infection, leading to death at 72h after infection. On the other hand, vaccinated mice displayed steadily pneumococcal numbers in the lungs in the first hours and a marked decrease 72h after challenge. In this group, pneumococci did not reach the bloodstream. Sera collected from WCP-PspA immunized mice displayed increased capacity of induction of complement deposition on bacteria surface, indicating a potential role of antibodies in the protection observed. Moreover, sera from WCP-PspA immunized mice protected naïve mice in passive immunization experiments. Conclusion: These results open the possibility for the combination of WCP vaccines with PspA, taking advantage of the adjuvant activity of WCP. Supported by: FAPESP, CNPq, Fundação Butantan.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192: When citing these abstracts please
Page 241: When citing these abstracts please
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?